Evidence map›Paper›PMID 42625053›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2026

Transarterial radioembolisation combined with targeted therapy and immune checkpoint inhibitors in advanced hepatocellular carcinoma with portal vein tumour thrombus: efficacy, safety, and dosimetric analysis.

Weifu Liu, Zhuting Fang, Mingzhi Hao, Yubin Hu, Shiguang Chen, Kongzhi Zhang, Xiaolong Wang, Zhangxian Chen, Wenchang Yu

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Weifu LiuDepartment of Oncology and Vascular Interventional Therapy, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.
Zhuting FangDepartment of Oncology and Vascular Interventional Therapy, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.
Mingzhi HaoDepartment of Oncology and Vascular Interventional Therapy, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.
Yubin HuDepartment of Oncology and Vascular Interventional Therapy, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.
Shiguang ChenDepartment of Oncology and Vascular Interventional Therapy, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.
Kongzhi ZhangDepartment of Oncology and Vascular Interventional Therapy, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.
Xiaolong WangDepartment of Oncology and Vascular Interventional Therapy, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.
Zhangxian ChenDepartment of Oncology and Vascular Interventional Therapy, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.
Wenchang YuDepartment of Oncology and Vascular Interventional Therapy, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China. ywc21jy@163.com.ORCID http://orcid.org/0000-0001-8239-6325

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeAdvanced hepatocellular carcinoma (HCC) with portal vein tumour thrombus (PVTT) carries a dismal prognosis. This study evaluated the efficacy and safety of transarterial radioembolisation (TARE) combined with targeted therapy and immune checkpoint inhibitors (ICIs) in patients with HCC and Vp2-Vp4 PVTT, and explored the tumour absorbed dose (TAD) threshold associated with survival benefit.

methodsWe retrospectively analysed 31 patients with HCC and Vp2-Vp4 PVTT treated with this triplet regimen. Tumour responses were assessed per mRECIST and RECIST 1.1. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method. The optimal TAD cutoff was identified through dose-threshold exploration and internally validated by bootstrap resampling.

resultsThe objective response rate was 77.4% per mRECIST and 54.8% per RECIST 1.1 (P = 0.023), with a disease control rate of 93.5%. Median PFS and OS were 10.0 months (95% CI, 7.9-NR) and 16.4 months (95% CI, 9.1-NR), respectively. Grade ≥ 3 treatment-related adverse events occurred in 22.6% of patients; no treatment-related death occurred. Exploratory analysis identified TAD ≥ 140 Gy as independently associated with improved PFS after multivariable adjustment (HR = 0.33, 95% CI, 0.11-0.95; P = 0.039), with a concordant trend for OS. Bootstrap validation confirmed robustness.

conclusionTARE combined with targeted therapy and ICIs demonstrates encouraging efficacy with an acceptable safety profile in advanced HCC with Vp2-Vp4 PVTT. TAD ≥ 140 Gy was associated with improved survival, providing a hypothesis-generating basis for personalised dosimetric optimisation in future prospective trials.

Indexed as

DosimetryHepatocellular carcinomaImmune checkpoint inhibitorPortal vein tumour thrombusTransarterial radioembolisationYttrium-90

Identifiers

PMID42625053

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.